NF-κB/IκB

Items 101-150 of 195

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. HDAC inhibitor

    UF010 is a potent and selective HDAC inhibitor with IC50 ~0.06 uM, 0.1 uM, 0.5 uM and 1.5 uM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.

  2. Analog of curcumin

    Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS.
  3. IKK2 inhibitor?€?

    AZD3264 is a novel IKK2 inhibitor.
  4. HDAC6 inhibitor

    ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.
  5. HDAC inhibitor

    BML-210 is HDAC inhibitor. BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.
  6. Anti-adipogenic, anti-inflammatory, and anti-neoplastic activities

    Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica. Triphala inhibits NF-κB activation. Triphala exerts antifungal action. Anti-adipogenic, anti-inflammatory, and anti-neoplastic activities.
  7. HDAC inhibitor

    ITSA-1 is membrane permeable and specifically suppresses TSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.
  8. ERK/Akt/NF-kB inhibitor

    Tomatidine inhibits the phosphorylation of ERK, Akt, and the nuclear content of NF-kB. possess anti-inflammatory properties.
  9. IKKε /TBK1 inhibitor

    Amlexanox is an anti-inflammatory antiallergic immunomodulator used to treat recurrent aphthous ulcers (canker sores), and (in Japan) several inflammatory conditions.
  10. IKK-ε inhibitor

    IKK epsilon-IN-1 is a potent IKKε inhibitor; inhibit the in-situ IKK ε-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM.
  11. Nrf2 activator

    CDDO-EA is an activator of Nrf2/ARE; Neuroprotective effect.
  12. NF-kB inhibitor

    The (+)-DHMEQ, the distomer of DHMEQ, is a inhibitor of NF-kB.
  13. NF-kB inhibitor

    (-)-DHMEQ, the eutomer of DHMEQ , is a newly developed NF-kB inhibitor, inhibits nuclear factor kB activation with IC50 value of 20 ug/mL, the activity is stronger than (+)-DHMEQ.

  14. Adjudin is a drug which is under development as a potential non-hormonal male contraceptive drug, which acts by blocking the production of sperm in the testes, but without affecting testosterone production.
  15. NF-kB inhibitor

    Pyrrolidinedithiocarbamate ammonium is a selective NF-kB inhibitor, inhibits translation of nitric oxide synthase mRNA to prevent induction.
  16. HDAC6 inhibitor

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
  17. HDAC/ER stress inhibitor

    Sodium phenylbutyrate is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.
  18. HDAC6 inhibitor

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).
  19. p53 activator / NF-κB inhibitor

    CBL0137(CBL-0137) activates p53 and inhibits NF-kB with EC50s of 0.37 μM and 0.47 μM in the cell-based p53 and NF-kB reporter assays, respectively. It also inhibits histone chaperone FACT (facilitates chromatin transcription complex).
  20. HDAC inhibitor

    SR-4370 is an HDAC inhibitor. SR-4370 exhibited IC50 values of 0.5 μM, 0.1 μM and 0.06 μM towards HDAC1, HDAC2 and HDAC3, resp.
  21. NF-kB inhibitor

    Withaferin A is a steroidal lactone present in W. somnifera that at 2-25 μM has been shown to bind to and induce aggregation of vimentin intermediate filaments in cultured endothelial cells and fibroblasts, causing apoptosis.
  22. Cynaropicrin is a sesquiterpene lactone originally isolated from artichoke (C. scolymus) that has diverse biological activities. It inhibits the growth of SKOV3, LOX-IMVI, A549, MCF-7, HCT15, and PC-3 cancer cells (IC50s = 1.1-8.7 μg/ml).
  23. HDAC8 inhibitor

    HDAC8-IN-1, is a HDAC8 inhibitor with an IC50 of 27.2 nM in cancer cell lines.
  24. FACT inhibitor

    CBL0137 is a FACT inhibitor that functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.
  25. NF-κB Inhibitor

    Ac2-26 is an active N-terminal peptide of annexin A1 (AnxA1).
  26. HDAC inhibitor

    Valproic acid is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2; Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
  27. Lipoic Acid, also known as R-(+)-alpha-Lipoic acid, is an organosulfur compound derived from octanoic acid. It is made in animals normally, and is essential for aerobic metabolism. It is also manufactured and is available as a dietary supplement in some countries where it is marketed as an antioxidant, and is available as a pharmaceutical drug in other countries.
  28. oncometabolite

    Fumaric acid is a fundamental unit of nucleic acids.. It is a oncometabolite or an endogenous, cancer causing metabolite. High levels of this organic acid can be found in tumors or biofluids surrounding tumors. Its oncogenic action appears to due to its ability to inhibit prolyl hydroxylase-containing enzymes.
  29. HDAC inhibitor

    Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.
  30. HDAC6 inhibitor

    SKLB-23bb is a potent and selective inhibitor for HDAC6 with an IC50 of 17 nM and shows 25-fold and 200-fold selectivity relative to HDAC1 (IC50=422 nM) and HDAC8 (IC50=3398 nM), respectively.
  31. HDAC inhibitor

    EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
  32. dual TBK1 and IKKε inhibitor

    TBK1/IKKε-IN-5 is a dual TBK1 and IKKε inhibitor, with IC50 values of 1 nM and 5.6 nM for TBK1 and IKKε, respectively.
  33. fluorescent substrate for HDAC

    Ac-Lys-AMC (Hexanamide), also termed MAL, is a fluorescent substrate for histone deacetylase HDACs.
  34. HDAC 11 inhibitor

    SIS17 is a potent and selective HDAC 11 inhibitor with an IC50 value of 0.83 μM. SIS17, is active in cells and inhibited the demyristoylation of a known HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.
  35. PDE5/HDAC-1 inhibitor

    CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer??s disease.
  36. HDAC inhibitor

    CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histonedeacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.
  37. HDAC6 inhibitor

    SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes.
  38. HDAC6 inhibitor

    SS-208 is a selective HDAC6 inhibitor, with an IC50 of 12 nM. SS-208 possesses anti-tumor activity in melanoma.
  39. HDAC inhibitor

    MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively.
  40. LTβR inhibitor

    LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor with an IC50 of 10 μM.
  41. HDAC inhibitor

    AES-135 is a potent HDAC inhibitor, inhibits HDAC3, HDAC6, HDAC11 with IC50s of 654, 190, and 636 nM, respectively. Anti-tumor activity.
  42. IKKα/IKKβ inhibitor

    INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively.
  43. HDAC6 inhibitor

    J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM.
  44. IκB kinase β inhibitor

    IMD-0560 is a novel IκB kinase β inhibitor.
  45. NIK inhibitor

    NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
  46. TBK1 inhibitor

    GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1.
  47. HDAC5/HDAC9 inhibitor

    BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.
  48. HDAC11 inhibitor

    FT895 is a potent and selective HDAC11 inhibitor with an IC50 of 3 nM.
  49. 4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities.
  50. HDAC1 /HDAC2 inhibitor

    ACY-957 is an orally active and selective inhibitor of HDAC1 and HDAC2, with IC50s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9.

Items 101-150 of 195

per page
Set Descending Direction